[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depressive-disorder-recurrent-in-remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depressive-disorder-recurrent-in-remission":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100580077","mindfulness-based-cognitive-therapy-mbct-for-the-prevention-of-depression-relapse-or-recurrence-using-videoconference-100580077",false,"NCT06832605","Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference","Effectiveness and Cost-Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference in the Spanish National Health System","BECOME","Inclusion Criteria:\n\n* Age over 18.\n* Diagnosis of recurrent major depressive disorder, with ≥ 2 previous major depressive episodes (MDD).\n* Current partial remission (no current depressive episode; a score ≥8 on the HDRS).\n* Internet access (via smartphone or personal computer).\n* Spanish literacy (spoken and written).\n\nExclusion Criteria:\n\n* Current or past psychosis, bipolar disorder, a history of schizophrenia, schizoaffective disorder, organic mental disorder, current severe substance abuse, organic brain damage, pervasive developmental delay, persistent antisocial behaviour, recent (in past 3 months) self-injury requiring clinical management or therapy according to medical records and clinical judgment.\n* Formal concurrent structured psychotherapy during the intervention period.\n* No experience in the use of new technologies (smartphones or computers).\n* Having completed a mindfulness-based structured training and\u002For extensive meditation experience (i.e., previous participation in meditation retreats (≥1) or regular (≥ weekly) meditation practice) in the previous year, or intending to commence meditation retreats or meditation practice during the study.","ALL","18 Years",{"count":20,"type":21},315,"ESTIMATED","INTERVENTIONAL",[24],"NA","Objectives: To evaluate the clinical- and cost-effectiveness of two delivery formats of mindfulness-based cognitive therapy (MBCT) - (i) MBCT delivered through eight videoconference group sessions (group MBCT), and (ii) MBCT delivered through a self-help manual plus three low-intensity videoconference group support sessions (supported MBCT self-help) - when added to treatment as usual (TAU; mental health outpatient care), compared with TAU alone, in patients with recurrent depression in partial remission. We will identify potential predictors and moderators of response and examine psychological mechanisms of change. Study design: Multicentre randomised controlled trial, with pre-post, 6- and 12-months follow-ups. Centres: Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat), Hospital Universitario Miguel Servet (Zaragoza), and Hospital del Mar (Barcelona). Participants: Adult patients (n=315) with recurrent depression in partial remission will be randomly assigned to group MBCT, supported MBCT self-help, or TAU. Primary outcome: time from randomisation to depressive relapse\u002Frecurrence at 12-month follow-up (DSM-5). Secondary outcomes: residual symptoms, well-being, quality of life, costs, and quality-adjusted life years. Process measures: rumination, mindfulness, decentering, affectivity, and self-compassion. Main statistical analyses: Hazard ratios will be calculated using survival analysis. Secondary outcomes, predictors, and moderators will be tested using regression-based approaches. Incremental cost-effectiveness ratios from healthcare system and societal perspectives will be estimated, alongside mediation analyses. Expectations and acceptability will be evaluated using qualitative methods. Conclusions: This study will inform the implementation of two accessible MBCT formats in Spain for preventing depressive relapse\u002Frecurrence. The use of different delivery formats will provide information on effectiveness, scalability, and value for money.",[27],"Major Depressive Disorder, Recurrent, in Remission",[29,30,31,32,33],"Depression","MBCT","Relapse\u002Frecurrence prevention","RCT","cost-effectiveness","NOT_YET_RECRUITING","2026-02-25",{"date":37,"type":38},"2026-02-27","ACTUAL",{"date":40,"type":21},"2026-04",{"date":42,"type":21},"2028-06",{"name":44,"class":45},"Fundació Sant Joan de Déu","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100471776","light-and-ion-maintenance-in-treatment-for-depression-limit-d-feasibility-study-100471776","NCT05423275","Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study","Inclusion Criteria:\n\n* Diagnostic and Statistical Manual (DSM-5) criteria for MDD, as determined by the Structured Clinical Interview for DSM-5 (SCID).\n* Taking a first-line antidepressant at approved doses (Table 1), with dose unchanged in the past month.\n* Participant desire to discontinue antidepressant treatment because of adverse effects or other reasons;\n* In remission as defined by score ≤10 on the clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) at both the screening visit and baseline visit, at least 2 weeks apart.\n* Willing and able to complete self-report and online assessments including sufficient fluency in English or French.\n\nExclusion Criteria:\n\n* Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime). Note that comorbid anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder) will not be excluded if the anxiety disorder is not the primary diagnosis.\n* Diagnosis of MDD with seasonal pattern (i.e., seasonal affective disorder, SAD) or with psychotic features (lifetime).\n* Significant personality disorder diagnosis \\[e.g., antisocial\\] by MINI and clinical assessment.\n* High suicidal risk, defined by clinician judgment.\n* History of alcohol or substance use disorder, with a severity of at least moderate or severe, within 6 months before screening.\n* Significant neurological disorders, head trauma, or other unstable medical conditions.\n* Regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers); Note - Stimulant medications for Attention-Deficit Hyperactivity Disorder are allowed if dose is stable in past month.\n* History of severe antidepressant discontinuation effects.\n* Retinal disease or other eye condition (e.g., macular degeneration) precluding the use of bright light treatment.\n* Use of photosensitizing medication (thioridazine, chloroquine, 8-methoxypsoralen) within 1 week of baseline visit.\n* Initiated formal psychotherapy (e.g., cognitive-behavioural therapy) within 3 months of Visit 1, or who plan to initiate psychotherapy during the study.\n* Continued use of any other evidence-based treatment for depression.","19 Years","65 Years",{"count":56,"type":21},100,[24],"Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of \"maintenance\" antidepressant treatment, after patients achieve symptom remission, to prevent relapse but many people stop antidepressants too soon relapse into another depressive episode. We will test non-medication treatments, negative ion therapy and light therapy, to see they can substitute for antidepressants to prevent relapse. This is a \"feasibility\" study to see if participants use study treatments properly, before doing a larger, definitive trial. In this 28-week study, 100 participants with MDD who are in remission with antidepressants will be treated with light therapy or negative ion therapy (with half of devices active and half inactive) while slowly discontinuing the antidepressant, and monitored for relapse.",[27],[61,62,63,64,65,66],"antidepressants","discontinuation","relapse prevention","light therapy","negative ions","depression","RECRUITING","2024-12-04",{"date":70,"type":38},"2024-12-09",{"date":72,"type":38},"2023-03-13",{"date":74,"type":21},"2027-06",{"name":76,"class":45},"University of British Columbia",1]